Needham & Company Bullish on Cytokinetics (CYTK) Into Omecamtiv Phase IIb Read-Out Midyear
Tweet Send to a Friend
Needham & Company reiterated its Buy rating and $2.50 price target on Cytokinetics (NASDAQ: CYTK) ahead of the Omecamtiv Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
